Despite an existing academic natural history study (Procstar) for Stargardt disease, AAVantgarde invested in running its own. This gave them a more rigorous and consistent dataset, collected with modern instruments over a shorter period, highlighting the strategic value of controlling baseline data for future pivotal trials.

After 10 years at his first company (J-Site) developing a therapy to slow disease, CEO Paul Bresge saw his daughter's condition advance. He founded Ray Therapeutics to target late-stage patients who had already lost photoreceptors, a more urgent and underserved population.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

AAVantgarde learned from its Usher syndrome trial that capturing patient-reported outcomes is essential, especially when traditional functional endpoints like eye charts are slow to change. This strategy ensures they capture meaningful data on patient quality of life, which can be crucial for demonstrating therapeutic benefit in slowly progressing diseases.

Instead of waiting years for traditional vision preservation data, Complement Therapeutics' trial prospectively uses novel endpoints like ellipsoid zone attenuation and focal microperimetry. These measures are designed to show a signal of efficacy earlier and correlate better with functional outcomes, addressing a key challenge in slowly progressing diseases.

For rare diseases without established clinical endpoints, biotech firms should co-design new endpoints with patients and their families. Presenting these patient-centric measures to the FDA builds a bond of trust and provides the agency with a clear, meaningful rationale for drug approval.

To avoid common gene therapy manufacturing delays, Ray Therapeutics invested heavily in its Chemistry, Manufacturing, and Controls (CMC) process early. They established a commercial-scale process *before* dosing a single patient, eliminating the risky and time-consuming transition from clinical to commercial material.

Many biotechs focus R&D solely on regulatory approval. Beren Therapeutics integrates commercial thinking early to ensure clinical development answers a different question: Is what we're building meaningful to patients, payers, and providers? This de-risks the asset for commercial success, not just clinical milestones.

Ocular Therapeutix's trial prioritized a primary endpoint designed to satisfy FDA requirements for a superiority label—a key regulatory win. However, the CEO stresses that clinicians use different metrics like OCT fluid, where their drug "easily beat Eylea." This highlights a crucial strategy: separate the endpoint needed for approval from the data that drives physician adoption.